Completed Enrollment

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

I8J-MC-JYCA -

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Solid Tumor
What the trial is testing?
Ramucirumab, Abemaciclib, Merestinib, LY3300054
Could I receive a Placebo?
No
Enrollment Goal
215
Trial Dates
Jun 29, 2016 - Jul 2024
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology

  • Participants entering the phase 1a dose escalation must submit, if available, an archival tumor tissue sample

  • Participants participating ONLY in the phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (3 years since last documented progression of disease.) biopsy

Participants Must Not:

  • Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids

  • Participant must not have a bowel obstruction or chronic diarrhea

  • Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment

  • Participant must not have received a live vaccine within 30 days before the first dose of study treatment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources